1-12 of 12
Khalid Mezzi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Carfilzomib, Daratumumab, and Dexamethasone (KdD) Vs Carfilzomib and Dexamethasone (Kd) for Relapsed/Refractory Multiple Myeloma (RRMM) in the Phase 3 Candor Study: Subgroup Analysis According to Renal Functioning

Meletios Athanasios Dimopoulos, Ola Landgren, David S. Siegel, Sebastian Grosicki, Albert Oriol, Rani Najdi, Chuang Li, Khalid Mezzi, Natalie Shu, Hang Quach
Journal: Blood
Blood (2023) 142 (Supplement 1): 2021.
https://doi.org/10.1182/blood-2023-190726
Published: 2023
Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1891.
https://doi.org/10.1182/blood-2019-127076
Published: 2019
Journal Articles

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

Clinical Trials & Observations
Meletios Dimopoulos, David Siegel, Darrell J. White, Ralph Boccia, Karim S. Iskander, Zhao Yang, Amy S. Kimball, Khalid Mezzi, Heinz Ludwig, Ruben Niesvizky
Journal: Blood
Blood (2019) 133 (2): 147–155.
https://doi.org/10.1182/blood-2018-06-860015
Published: 2019
Includes: Supplemental data
Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3253.
https://doi.org/10.1182/blood-2018-99-113519
Published: 2018
Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study

Ola Landgren, MD PhD, David S Siegel, MD PhD, Daniel Auclair, PhD, Ajai Chari, MD, Michael Boedigheimer, Tim Welliver, MD PhD, Khalid Mezzi, Karim Iskander, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 799.
https://doi.org/10.1182/blood-2018-99-112289
Published: 2018
Journal Articles

Identifying Ultra-High Risk Smoldering Multiple Myeloma

Theresia Akhlaghi, BS, Even H Rustad, MD, Venkata D Yellapantula, Neha Korde, MD, Sham Mailankody, MBBS, Nikoletta Lendvai, MD PhD, Alexander M. Lesokhin, MD, Hani Hassoun, MD, Sergio Giralt, MD, Heather J. Landau, MD, Eric L. Smith, MD PhD, Gunjan L. Shah, MD, Michael Scordo, MD, David J. Chung, MD PhD, Khalid Mezzi, Monica Khurana, Megan Braunlin, Winifred Werther, Ola Landgren, MD PhD, Malin Hultcrantz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3192.
https://doi.org/10.1182/blood-2018-99-109709
Published: 2018
Journal Articles

Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study

Meletios A. Dimopoulos, David Siegel, MD PhD, Darrell J. White, MD, Ralph V. Boccia, Zhao Yang, Amy S. Kimball, Karim Saad Iskander, Khalid Mezzi, MD MBA, Heinz Ludwig, MD, Ruben Niesvizky, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1845.
https://doi.org/10.1182/blood.V130.Suppl_1.1845.1845
Published: 2017
Journal Articles

Demographic and Clinical Characteristics of Multiple Myeloma (MM) Patients Treated with Carfilzomib-Based Regimens in a Real World Setting

Christopher Kim, PhD, Winifred Werther, Karim Saad Iskander, Michael Gruber, Khalid Mezzi, MD MBA
Journal: Blood
Blood (2017) 130 (Supplement 1): 5441.
https://doi.org/10.1182/blood.V130.Suppl_1.5441.5441
Published: 2017
Journal Articles

Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting

Robert M Rifkin, MD, E Susan Amirian, PhD MS, Rohan Medhekar, PhD, Thomas Wilson, PhD DrPH, Marley Boyd, MS, Khalid Mezzi, MD MBA, Sumeet Panjabi, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3433.
https://doi.org/10.1182/blood.V130.Suppl_1.3433.3433
Published: 2017
Journal Articles

A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting

Robert M Rifkin, MD, Rohan Medhekar, PhD, E Susan Amirian, PhD MS, Thomas Wilson, PhD DrPH, Marley Boyd, MS, Khalid Mezzi, MD MBA, Sumeet Panjabi, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3434.
https://doi.org/10.1182/blood.V130.Suppl_1.3434.3434
Published: 2017
Journal Articles

Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis

Ajai Chari, MD, Sanjay K. Aggarwal, Khalid Mezzi, Kenneth Wang, Christopher Kim, Shao Zhu, Megan Braunlin, Winifred Werther, Joseph Mikhael, MD
Journal: Blood
Blood (2016) 128 (22): 3319.
https://doi.org/10.1182/blood.V128.22.3319.3319
Published: 2016
Journal Articles

Treatment Sequencing Patterns in Medicare-Enrolled Patients with Multiple Myeloma

Shuling Li, PhD, Tanya Natwick, Akeem Yusuf, Irena Sarah Vidito, Khalid Mezzi, Winifred Werther
Journal: Blood
Blood (2016) 128 (22): 2120.
https://doi.org/10.1182/blood.V128.22.2120.2120
Published: 2016